Caladrius Biosciences, Inc.

Welcome to the Caladrius Biosciences 3rd Quarter 2021 Financial Results and Business Update conference call. Currently, all participant lines are in a listen-only mode. Following management's prepared remarks, there will be a question and answer session. To ask a question at that time, please press the star key followed by the 1 on your touchtone phone. If anyone has difficulty hearing the conference call, please press star 0 for the operator assistance. As a reminder, this call is being recorded today, Thursday, November 4th, 2021. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead, sir.

Thank you, operator, and good afternoon, everyone. Welcome to Caladrius' third quarter 2021 conference call to discuss our financial results and provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer, Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer, and James Nisko, Vice President of Finance and Treasury. Earlier today, we issued a press release announcing our third quarter 2021 financial results, which is available under the investors and news section of the company website, along with the webcast replay of this call. If you have not received this news release or would like to be added to the company's email distribution list, please email me at jmendito at collateralist.com. Before we begin, I will remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Colliderist. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its forms 10-K, 10-Q, and 8-K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of live broadcast, Thursday, November 4th, 2021. Colleges Biosciences undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. Please keep in mind that the company continues to conduct calls from different locations during the COVID-19 pandemic, so we appreciate your patience should we have any technical difficulties. With that, I'll now turn the call over to Dr. Mazzo. Dave?

Thank you, John, and good afternoon, everyone. As always in these continued trying times, I hope you are all in good health and remain safe. Thank you for joining us today on our third quarter business update conference call. During this quarter, Caladrius continued to advance and optimize its CD34 positive cell technology-based clinical programs while maintaining a strong financial position that will fund operations for the next several years, all this despite the challenging environment brought on by the COVID-19 pandemic. Notably, the company strengthened and further diversified its operations and management team with the addition of several highly qualified and experienced personnel including the appointment of Kristen K. Buck, MD, as Executive Vice President of Research and Development and Chief Medical Officer. Kristen's wealth of knowledge and extensive medical, regulatory, and safety expertise across many therapeutic areas will prove instrumental during the company's evolution as we continue to advance and expand our clinical development programs and execute upon our vision. Kristen is particularly adept at focusing research and development on product development and already has made great impact on the execution and efficiency of our current programs. We are delighted to have someone of her caliber as part of our executive team here at Caladrius, and you will have the opportunity to hear from her firsthand as she will provide an update on our clinical development programs in a few moments. Before that, though, I'll turn the call over to James Nisko, our Vice President of Finance and Treasury, to review and provide commentary on our financial results for the quarter. James?